Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY03020 in Healthy Chinese Adults
NCT06556966Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia and Alzheimer's disease (AD) comparing LY03020 with Placebo (2 arms). Primary endpoint: Frequency of adverse events (AEs) up to 144 hours. Started Aug 2024; status: completed.
02
Drugs
lpm787000048 maleate
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06556966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556966.